

## **Omni Bioceutical Innovations**

Jane Christensen, CEO

(602) 300-8199

jane@omnibioinnovations.com

omnibioinnovations.com

## **Omni Bioceutical Innovations**

**Company Overview:** Omni Bioceutical Innovations creates and licenses patent-protected technology, formulates and manufactures products, and provides consulting in dermatocosmetic fields. Its technology has been validated by providing solutions to the \$10B global medical aesthetic, \$117B global skincare, and \$4B U.S. hair loss treatment markets through innovative skin and hair care products that reduce post-aesthetic procedure downtime, decrease inflammation, and improve results. The strength behind Omni is its patented processes, exclusive licenses, and IP. These include unique wound care based ingredients like human stem cell growth factors (HGF), peptides, and the patented delivery molecule, M-007®.

**Product/Service Overview:** Omni offers HGF products that provide aesthetic patients with superior recovery after medical aesthetic procedures and hair growth treatments. For example, CO2 laser treatments typically require a 7-10 day recovery. Using Omni's CORE Recovery Serum, this down time is reduced to 2-5 days. Omni currently offers specialized serums for hair, lash & brow growth, and daily face and eye application. These products have been tested in observational studies and have been shown to improve skin within 3 weeks and hair growth within 6 weeks.

Most cosmetic ingredients sit on the surface of the skin since the molecules are too large to pass through the skin's protective barrier. To solve this problem and deliver those ingredients to their intended target areas, Omni has developed M-007®: a patented target specific transporter/carrier molecule that assists in the delivery and absorption of active ingredients making them more bioavailable. M-007® is patented in the U.S., Canada, Australia, Korea, Japan and the EU with other countries being added in the near future. No other products on the market have a patented molecular delivery system like Omni's.

**Market Opportunity:** Omni reaches product users through two channels: physicians/med-spas and private label clients. Physicians pair Omni's regenerative products with in-office aesthetic treatments and sell versions to patients for at-home use. According to ASAPS, the number of non-surgical aesthetic procedures was up 4.2% to 3.2M in 2017. Omni's serums pair well with micro and full ablative laser resurfacing procedures, which were up 99.5% and 29.2%, respectively, in 2017. The growth rates for these segments are expected to continue in the double-digits primarily due to a rapidly aging population, new technologies, physicians adding lasers to increase cash pay treatments, and the demand by consumers for less surgery.

Private label clients contract Omni to formulate, manufacture, and supply products using Omni's proprietary processes and ingredients. The M-007® technology has opened up new recurring revenue streams: licensing and supply agreements. Not only can M-007® be licensed in the aesthetic industry, but it can also be licensed for use in other industries including agricultural, pharmaceutical, nutraceutical, and more.

### **Management Team & Advisors:**

**Jane Christensen**, CEO – 35+ years of start-up ventures including medical, beauty & wellness, and educational companies

**Ron Carpenter**, MBA, COO – 25+ years of operational, corporate strategy, and financial management experience

**Kerwin Yamanaka**, R&D Formulator – 30+ years of skincare formulation experience; lead formulator for Philosophy

**Gary Black**, PhD, CSO – Global leader in molecular physics; creator of numerous patents, and consultant to the UN, DOD, FDA

**Molly Iarocci**, MBA – Business development, business structuring, and corporate finance expert

**Grant Russell** – Manufacturing, sales chain management, and regulatory expert